5.32 USD
↘ 0.21 (3.71%)AT CLOSE (11:59 AM EDT)
Aclaris Therapeutics, Inc.
ACRSNASDAQ • USD
5.37
↗ 0.05 (0.94%)
POST MARKET (AS OF 07:36 PM EDT)
Post Market
AS OF 07:36 PM EDT
5.37
↗ 0.05 (0.94%)
Market: CLOSED
ACRS is currently priced at $5.32. Both sides of the analysis point lower: technicals flash "Strong Sell" and fundamentals confirm with a "Sell" reading. Key drivers include a concerning Altman Z-Score in the distress zone, a weak Piotroski F-Score of 1/9, negative Return on Equity and a bullish Golden Cross on the moving averages. Furthermore, ACRS is currently richly valued, trading at a premium to sector peers across key valuation metrics.
Technical & fundamental data as of Sep 16, 2026.
Open?$5.54
High?$5.56
Low?$4.98
Prev. Close?$5.53
Volume?5.8M
Avg. Volume?2.2M
VWAP?$5.19
Rel. Volume?2.58x
Bid / Ask
Bid?$5.35 × 400
Ask?$5.58 × 100
Spread?$0.23
Midpoint?$5.47
Valuation & Ratios
Market Cap?783.1M
Shares Out?139.8M
Float?121.5M
Float %?86.9%
P/E Ratio?N/A
P/B Ratio?6.29
EPS?-$0.51
Dividend?0.00%
Ex-Dividend?N/A
News
Profile
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company. It focuses on developing novel drug candidates for immuno-inflammatory diseases using its proprietary KINect drug discovery platform. The company's pipeline consists of the following key product candidates: Bosakitug (ATI-045), an investigational, novel, humanized anti-TSLP monoclonal antibody being developed for patients with severe asthma, COPD, and chronic rhinosinusitis with nasal polyps; ATI-2138, being developed for the potential treatment of T cell-mediated autoimmune diseases; and ATI-052 and ATI-9494. Additionally, it has an investigational product candidate, Lepzacitinib (ATI-1777), which is being focused upon as a potential treatment for atopic dermatitis and potentially other dermatologic conditions.
Employees
73
Market Cap
813.3M
Industry
PHARMACEUTICAL PREPARATIONS
Website
Listed
2015-10-07
Address
701 LEE ROAD
WAYNE, PA 19087
Phone: 484-324-7933
WAYNE, PA 19087
Phone: 484-324-7933
Technical OutlookStrong Sell
Strong SellNeutralStrong Buy
Long-Term (Tide)?▼ Bearish(-1/3)
Medium-Term (Wave)?▼ Bearish(-3/3)
Short-Term (Ripple)?▼ Bearish(-3/3)
MA Alignment?Mixed
Full Technical Analysis →Fundamental OutlookSell
Strong SellNeutralStrong Buy
F-Score?6
Z-Score?1
Momentum?57
Short Sent.?54
Piotroski F-Score?1/9Weak
Altman Z-Score?-0.41Distress
Confidence?60%Moderate
Short InterestHigh
Short % of Float?12.49%High
Short Interest?15.2M
Days to Cover?8.7
Free Float121.5M
Avg Daily Volume1.8M
Settlement Date2026-08-31
Financial Health
Current Ratio?3.46Strong
Quick Ratio?3.46Strong
Cash Ratio?0.68Adequate
Debt/Equity?0.00Low
ValuationFAIRLY VALUEDvs 1 peers + S&P 500
Score58/100
P/E?N/A▾
P/B?6.29FAIR▾
Peers100
S&P29
P/S?95.28HIGH▾
Peers100
S&P3
P/FCF?N/A▾
EV/EBITDA?-9.0CHEAP▾
S&P97
EV/Sales?92.95HIGH▾
Peers100
S&P3
Returns & Efficiency
ROE?-60.8%WEAK▾
S&P3
ROA?-42.2%WEAK▾
S&P3
Cash Flow & Enterprise
FCF?$-62177000
Enterprise Value?$763.9M
Fundamentals ratios updated end of day